Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists

- Glewis, Sarah, Lingaratnam, Senthil, Krishnasamy, Michael, Martin, Jennifer H., Tie, Jeanne, Alexander, Marliese, Michael, Michael

Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

- Flynn, Alexandra, Galettis, Peter, Gurney, Howard, Michael, Michael, Desar, Ingrid, Westerdijk, Kim, Schneider, Jennifer, Martin, Jennifer

Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey.

- Glewis, Sarah, Krishnasamy, Mei, Campbell, Ian, Martin, Jennifer H., Tie, Jeanne, Alexander, Marliese, Michael, Michael, Lingaratnam, Senthil, Harris, Sam, Underhill, Craig, Georgiou, Chloe, Warren, Mark, Campbell, Robert, IJzerman, Maarten, Fagery, Mussab

A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing

- Glewis, Sarah, Alexander, Marliese, Khabib, Muhammad N. H., Brennan, Annabelle, Lazarakis, Smaro, Martin, Jennifer, Tie, Jeane, Lingaratnam, Senthil, Michael, Michael

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

- White, Cassandra, Scott, Rodney J., Paul, Christine, Ziolkowski, Andrew, Mossman, David, Fox, Stephen B., Michael, Michael, Ackland, Stephen

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

- Liu, Zheng, Martin, Jennifer H., Hatzimihalis, Athena, Campbell, Ian, Crowley, Simone, Beale, Phillip J., Karapetis, Christos S., Price, Timothy, Burge, Mathew E., Michael, Michael, Liauw, Winston, Mclachlan, Sue-Anne, Link, Emma, Matera, Anetta, Thompson, Michael, Jefford, Michael, Hicks, Rod J., Cullinane, Carleen